Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 2, 2010, Pages 301-309

  Giovacchini, Giampiero ^a   Picchio, Maria ^b   Coradeschi, Elisa ^a   Bettinardi, Valentino ^b   Gianolli, Luigi ^b   Scattoni, Vincenzo ^b   Cozzarini, Cesare ^b   Di Muzio, Nadia ^b   Rigatti, Patrizio ^b   Fazio, Ferruccio ^a,b   Messa, Cristina ^a,c,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CNR   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

11C Choline PET CT; Biochemical failure; Predictive factors; Prostate cancer

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FOLLOW UP; HISTOLOGY; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; ITALY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77749249079     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1253-3     Document Type: Article

References (40)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor, et al. 2005 Cancer statistics, 2005 CA Cancer J Clin 55 10 30 10.3322/canjclin.55.1.10 15661684
2. O Dillioglugil BD Leibman MW Kattan C Seale-Hawkins TM Wheeler PT Scardino 1997 Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer Urology 50 93 99 10.1016/S0090-4295(97) 00106-4 1:STN:280:DyaK2szmtFWgsw%3D%3D 9218025 (Pubitemid 27300370)
3. CR Pound AW Partin MA Eisenberger DW Chan JD Pearson PC Walsh 1999 Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1591 1597 10.1001/jama.281.17.1591 1:STN:280: DyaK1M3kvFagsg%3D%3D 10235151 (Pubitemid 29211767)
4. IJ de Jong J Pruim PH Elsinga W Vaalburg HJ Mensink 2003 [11C]choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 32 38 10.1016/S0302-2838(03)00207-0 12814672 (Pubitemid 36741372)
5. M Picchio C Messa C Landoni L Gianolli S Sironi M Brioschi, et al. 2003 Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography J Urol 169 1337 1340 10.1097/01.ju.0000056901.95996.43 1:CAS:528: DC%2BD3sXhvFahs7o%3D 12629355 (Pubitemid 36323779)
6. DT Schmid H John R Zweifel T Cservenyak G Westera GW Goerres, et al. 2005 Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 623 628 10.1148/radiol.2352040494 15858102 (Pubitemid 40571106)
7. M Cimitan R Bortolus S Morassut V Canzonieri A Garbeglio T Baresic, et al. 2006 [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387 1398 10.1007/s00259-006-0150-2 16865395 (Pubitemid 44885404)
8. SN Reske NM Blumstein G Glatting 2008 [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy Eur J Nucl Med Mol Imaging 35 9 17 10.1007/s00259-007-0530-2 17828534 (Pubitemid 350234137)
9. M Heinisch A Dirisamer W Loidl F Stoiber B Gruy S Haim, et al. 2006 Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5 ng/ml? Mol Imaging Biol 8 43 48 10.1007/s11307-005-0023-2 16315004 (Pubitemid 44193401)
10. V Scattoni M Picchio N Suardi C Messa M Freschi M Roscigno, et al. 2007 Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy Eur Urol 52 423 429 10.1016/j.eururo.2007.03.032 17397992 (Pubitemid 46963456)
11. H Vees F Buchegger S Albrecht H Khan D Husarik H Zaidi, et al. 2007 (18)F-choline and/or (11)C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy BJU Int 99 1415 1420 10.1111/j.1464-410X.2007.06772.x 1:CAS:528:DC%2BD2sXotFansLw%3D 17428249 (Pubitemid 47164795)
12. DB Husarik R Miralbell M Dubs H John OT Giger A Gelet, et al. 2008 Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 253 263 10.1007/s00259-007-0552-9 17926036
13. BJ Krause M Souvatzoglou M Tuncel K Herrmann AK Buck C Praus, et al. 2008 The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 18 23 10.1007/s00259-007-0581-4 1:CAS:528:DC%2BD2sXhsVSmtLbO 17891394 (Pubitemid 350234152)
14. M Bergstrom L Eriksson C Bohm G Blomqvist J Litton 1983 Correction for scattered radiation in a ring detector positron camera by integral transformation of the projections J Comput Assist Tomogr 7 42 50 10.1097/00004728-198302000-00166 1:STN:280:DyaL3s7js1Ggsg%3D%3D 6600755
15. V Bettinardi M Danna A Savi M Lecchi I Castiglioni MC Gilardi, et al. 2004 Performance evaluation of the new whole-body PET/CT scanner: Discovery ST Eur J Nucl Med Mol Imaging 31 867 881 10.1007/s00259-003-1444-2 14770270
16. V Bettinardi P Mancosu M Danna G Giovacchini C Landoni M Picchio, et al. 2007 Two-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study Q J Nucl Med Mol Imaging 51 214 223 1:STN:280:DC%2BD2szmtlGisg%3D%3D 17464266
17. C Messa V Bettinardi M Picchio E Pelosi C Landoni L Gianolli, et al. 2004 PET/CT in diagnostic oncology Q J Nucl Med Mol Imaging 48 66 75 1:STN:280:DC%2BD2czktFaluw%3D%3D 15243404
18. MW Fagerland DW Hosmer AM Bofin 2008 Multinomial goodness-of-fit tests for logistic regression models Stat Med 27 4238 4253 10.1002/sim.3202 18203120
19. DW Hosmer NL Hjort 2002 Goodness-of-fit processes for logistic regression: simulation results Stat Med 21 2723 2738 10.1002/sim.1200 12228887 (Pubitemid 35049341)
20. J Kotzerke BG Volkmer G Glatting J van den Hoff JE Gschwend P Messer, et al. 2003 Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer Nuklearmedizin 42 25 30 1:CAS:528:DC%2BD3sXjslegtL4%3D 12601451
21. L Cheng H Zincke ML Blute EJ Bergstralh B Scherer DG Bostwick 2001 Risk of prostate carcinoma death in patients with lymph node metastasis Cancer 91 66 73 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P 1:STN:280:DC%2BD38%2Fgs1Sksg%3D%3D 11148561 (Pubitemid 32052615)
22. L Salomon AG Anastasiadis CW Johnson JM McKiernan ET Goluboff CC Abbou, et al. 2003 Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression Urology 62 304 309 10.1016/S0090-4295(03)00373-X 12893340 (Pubitemid 36952082)
23. OK Macdonald AV D'Amico N Sadetsky DC Shrieve PR Carroll 2008 Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSUREtrade mark database Urol Oncol 26 271 275 18452818
24. FA Vicini EL Ziaja LL Kestin DS Brabbins JS Stromberg JA Gonzalez, et al. 1999 Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer Urology 54 111 117 10.1016/S0090-4295(99) 00219-8 1:STN:280:DyaK1MzktFOjsA%3D%3D 10414736 (Pubitemid 29323342)
25. C Obek S Lai S Sadek F Civantos MS Soloway 1999 Age as a prognostic factor for disease recurrence after radical prostatectomy Urology 54 533 538 10.1016/S0090-4295(99)00168-5 1:STN:280:DyaK1Mvgt1emsA%3D%3D 10475367 (Pubitemid 29407034)
26. SJ Freedland JC Presti Jr CJ Kane WJ Aronson MK Terris F Dorey, et al. 2004 Do younger men have better biochemical outcomes after radical prostatectomy? Urology 63 518 522 10.1016/j.urology.2003.10.045 15028449
27. M Ribeiro P Ruff G Falkson 1997 Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer Am J Clin Oncol 20 605 608 10.1097/00000421-199712000-00015 1:STN:280:DyaK1c%2FltlSgug%3D%3D 9391550 (Pubitemid 27509888)
28. H Gronberg JE Damber H Jonsson P Lenner 1994 Patient age as a prognostic factor in prostate cancer J Urol 152 892 895 1:STN:280:DyaK2czivVelug%3D%3D 8051746
29. G Giovacchini M Picchio E Coradeschi V Scattoni V Bettinardi C Cozzarini, et al. 2008 [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy Eur J Nucl Med Mol Imaging 35 1065 1073 10.1007/s00259-008-0716-2 1:CAS:528:DC%2BD1cXlvVClt78%3D 18200444
30. UG Mueller-Lisse MG Swanson DB Vigneron H Hricak A Bessette RG Males, et al. 2001 Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging Magn Reson Med 46 49 57 10.1002/mrm.1159 1:CAS:528:DC%2BD3MXltlShsr0%3D 11443710 (Pubitemid 32592138)
31. DB Agus DW Golde G Sgouros A Ballangrud C Cordon-Cardo HI Scher 1998 Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal Cancer Res 58 3009 3014 1:CAS:528:DyaK1cXkvVCnu7k%3D 9679964
32. T Hara A Bansal TR DeGrado 2006 Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells Nucl Med Biol 33 977 984 10.1016/j.nucmedbio.2006.08.002 1:CAS:528:DC%2BD28Xht1Cls7%2FF 17127170 (Pubitemid 44791951)
33. DT Price RE Coleman RP Liao CN Robertson TJ Polascik TR DeGrado 2002 Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 273 280 10.1016/S0022-5347(05)64906-3 12050555
34. TR DeGrado SW Baldwin S Wang MD Orr RP Liao HS Friedman, et al. 2001 Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers J Nucl Med 42 1805 1814 1:CAS:528:DC%2BD38XktlOktb8%3D 11752077
35. J Kotzerke J Prang B Neumaier B Volkmer A Guhlmann K Kleinschmidt, et al. 2000 Experience with carbon-11 choline positron emission tomography in prostate carcinoma Eur J Nucl Med 27 1415 1419 10.1007/s002590000309 1:STN:280:DC%2BD3cvltFyguw%3D%3D 11007527 (Pubitemid 30680634)
36. C Testa R Schiavina R Lodi E Salizzoni B Corti M Farsad, et al. 2007 Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT Radiology 244 797 806 10.1148/radiol.2443061063 17652190 (Pubitemid 47292091)
37. D Visvikis D Griffiths DC Costa J Bomanji PJ Ell 2005 Clinical evaluation of 2D versus 3D whole-body PET image quality using a dedicated BGO PET scanner Eur J Nucl Med Mol Imaging 32 1050 1056 10.1007/s00259-005-1809-9 1:STN:280:DC%2BD2Mrpsleiug%3D%3D 15846487 (Pubitemid 41339280)
38. G El Fakhri PA Santos RD Badawi CH Holdsworth AD Van Den Abbeele MF Kijewski 2007 Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET J Nucl Med 48 1951 1960 10.2967/jnumed.108.007369 18006613 (Pubitemid 350232303)
39. C Lartizien C Comtat PE Kinahan N Ferreira B Bendriem R Trebossen 2002 Optimization of injected dose based on noise equivalent count rates for 2- and 3-dimensional whole-body PET J Nucl Med 43 1268 1278 12215569
40. HI Scher S Halabi I Tannock M Morris CN Sternberg MA Carducci, et al. 2008 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 1148 1159 10.1200/JCO.2007.12.4487 18309951